
The nucleic acid drug developer previously secured $18m in a series A round backed by contract research company SNBL in February 2015.
The Delta Electronics-backed company, which has developed an artificial heart for transplants, has filed for a $40m initial public offering on Nasdaq.
Existing investor Tate and Lyle returned to back Evolve BioSystems' latest round, which will fund pre-commercialisation activities for its probiotics products.
Newly launched genomics company Helix has secured investment from founding partners including Illumina, and additional cash from strategic partner Mayo Clinic.
Pfizer and Ipsen, both of which previously backed Rhythm Metabolic's parent company, contributed to the obesity treatment developer's series A round.
Ascentage Pharma, a spin-out of oncology company Ascenta Therapeutics, received $3m in funding from biotechnology company 3SBio in February.
The healthcare IT technology developer's series B round follows a $4m round in 2013 backed by telecommunications company Rogers Communications.
Manish Kothari was previously a director of commercial ventures and licensing at the corporate venturing unit, after initially joining SRI in 2013.